← Back to Clinical Trials
Recruiting NCT06882603

NCT06882603 Efficacy of Corticosteroid Injection and Nerve Hydrodissection in Carpal Tunnel Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06882603
Status Recruiting
Phase
Sponsor Kirsehir Ahi Evran Universitesi
Condition Carpal Tunnel Syndrome (CTS)
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-10-14
Primary Completion 2026-02-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
hydrodissectionSteroid injectionExercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-10-14 with a primary completion date of 2026-02-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The subject of the study is to use current treatment methods in patients with nerve compression in the wrist and compare their effects. The purpose of the study is to determine the most appropriate method by comparing the benefits of cortisone and serum injection in addition to exercise therapy in volunteers like you who have nerve compression in the wrist and have pain and numbness.

Eligibility Criteria

Inclusion Criteria: 1. Female and male patients aged 18-65 who applied to Ahi Evran University Physical Medicine and Rehabilitation Polyclinic and diagnosed with carpal tunnel syndrome through clinical and EMG 2. Patients who can understand the information form correctly and are cooperative 3. Patients who consented to participate in the study according to the informed consent form Exclusion Criteria: 1. Cervical radiculopathy 2. Polyneuropathy 3. Brachial plexopathy 4. Systemic corticosteroid use 5. History of fracture and trauma in the forearm and wrist on the treated side 6- Inflammatory rheumatic disease 7- Pregnant and breastfeeding patients 8- Systemic diseases such as renal failure, peptic ulcer, diabetes, hypothyroidism, coagulation disorders 9- Patients who have undergone carpal tunnel syndrome surgery 10- Thoracic outlet syndrome 11- Thenar atrophy, severe carpal tunnel syndrome 12- Patient is unwilling or states that they cannot participate for any reason

Contact & Investigator

Central Contact

Basak Cigdem Karacay, Assoc. Prof.

✉ basakcigdem@hotmail.com

📞 +905445094803

Principal Investigator

Basak Cigdem Karacay, Assoc. Prof

PRINCIPAL INVESTIGATOR

Kirsehir Ahi Evran Universitesi

Frequently Asked Questions

Who can join the NCT06882603 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Carpal Tunnel Syndrome (CTS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06882603 currently recruiting?

Yes, NCT06882603 is actively recruiting participants. Contact the research team at basakcigdem@hotmail.com for enrollment information.

Where is the NCT06882603 trial being conducted?

This trial is being conducted at Kırşehir, Turkey (Türkiye), Kırşehir, Turkey (Türkiye).

Who is sponsoring the NCT06882603 clinical trial?

NCT06882603 is sponsored by Kirsehir Ahi Evran Universitesi. The principal investigator is Basak Cigdem Karacay, Assoc. Prof at Kirsehir Ahi Evran Universitesi. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology